The Acute Effects of Liquid IV's Pre-Workout Supplement on Muscle Endurance & Strength, Energy, and Cognition

NCT07225608 | Completed

• 1 other identifier: Pro00089370
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to learn if a new pre-workout supplement can improve exercise performance in healthy adults. It will also look at how the supplement affects mood and energy levels. The main questions it aims to answer are: Does the pre-workout supplement improve endurance and strength during exercise? Does it reduce how hard exercise feels (perceived exertion)? How does it affect participants' mood and energy? Researchers will compare the pre-workout supplement to a placebo (a look-alike powder that contains no active ingredients) to see if it works. Participants will: Take the pre-workout supplement or a placebo before exercise in two separate sessions; Complete exercise tests after taking each one; Report how they feel during and after exercise, including mood, energy, and effort. By bridging gaps in existing research, this study aims to establish a robust scientific foundation for the application of this novel pre-workout supplement in enhancing exercise outcomes.

Conditions

Exercise Performance; Endurance Exercise; Mood; Physical Performance; Perceived Exertion; Energy

Keywords

physical performance; exercise performance; endurance exercise; perceived exertion; strength endurance; mood; energy; L-theanine; Rhodiola Rosea; Creatine

Outcome Measures

Primary Outcomes (5)

• Aerobic Endurance (Graded Cycling Test VO₂max )

  Participants will complete a graded cycling test on a calibrated cycle ergometer to assess aerobic performance. Maximal oxygen consumption (VO₂max) will be noted if a plateau is observed. using a metabolic cart to determine VO₂max.VO₂max represents the highest rate of oxygen consumption achieved during the test. Proper cycle ergometer setup, including seat height and handlebar position, will be standardized for all participants. Testing will be conducted by trained technicians for consistency.

  From baseline 70 minutes after treatment consumption, then again on day 6, 70 minutes post treatment consumption

• Local Muscular Endurance (Bench Press to Failure)

  Participants will complete bench press assessments to evaluate muscular strength and endurance. A 5-repetition maximum (5RM) protocol will be used to determine maximal bench press strength. For muscular endurance, participants will complete two sets of bench press at 60% of their 1RM, performing repetitions to fatigue with 2 minutes of rest between sets. Total work volume will be calculated as the product of sets × repetitions. Proper spotting and form supervision will be ensured throughout.

  From baseline 50 minutes post treatment consumption, then again on day 6, 50 minutes post treatment consumption

• Aerobic Endurance (Graded Cycling Test VO₂peak)

  Participants will complete a graded cycling test on a calibrated cycle ergometer to assess aerobic performance. Oxygen consumption (VO₂) will be continuously monitored every 15 seconds using a metabolic cart to determine VO₂peak. Peak oxygen consumption will be recorded as the highest oxygen uptake value observed during the incremental test. Proper cycle ergometer setup, including seat height and handlebar position, will be standardized for all participants. Testing will be conducted by trained technicians for consistency.

  From baseline 70 minutes after treatment consumption, then again on day 6, 70 minutes post treatment consumption

• Aerobic Endurance (Graded Cycling Test Time to Exhaustion)

  Participants will complete a graded cycling test on a calibrated cycle ergometer to assess aerobic performance. The total duration in minutes participants are able to sustain the incremental cycling workload until volitional fatigue is recorded. This measures endurance capacity during the graded test. Proper cycle ergometer setup, including seat height and handlebar position, will be standardized for all participants. Testing will be conducted by trained technicians for consistency.

  From baseline 70 minutes after treatment consumption, then again on day 6, 70 minutes post treatment consumption

• Aerobic Endurance (Graded Cycling Test Total Work Performed)

  Participants will complete a graded cycling test on a calibrated cycle ergometer to assess aerobic performance. Total work (kJ) will be calculated as Σ(power × time)/1000, where power = kp × 50 RPM × 6.118.. This reflects overall exercise performance. Proper cycle ergometer setup, including seat height and handlebar position, will be standardized for all participants. Testing will be conducted by trained technicians for consistency.

  From baseline 70 minutes after treatment consumption, then again on day 6, 70 minutes post treatment consumption

Secondary Outcomes (8)

• Thayer Activation-Deactivation Adjective Checklist (ADACL)

  From baseline, 10 minutes pre treatment consumption, then 35 minutes after treatment consumption, and then again 90 minutes post treatment consumption. Until repeated on day 6.

• Samn-Perelli Visual Analog Scale (VAS)

  From baseline, 10 minutes pre treatment consumption, then 35 minutes after treatment consumption, and then again 90 minutes post treatment consumption. Until repeated on day 6.

• Caffeine Visual Analog Scale (VAS)

  From baseline, 10 minutes pre treatment consumption, then 35 minutes after treatment consumption, and then again 90 minutes post treatment consumption. Until repeated on day 6.

• Muscle Strength and Strength Endurance (Isometric Mid Thigh Pull)

  From baseline 40 minutes after treatment consumption, then again on day 6, 40 minutes post treatment consumption

• Lower Body Power and Force Generation (Maximal Countermovement Jump)

  From baseline 45 minutes after treatment consumption, then again on day 6, 45 minutes post treatment consumption

Study Arms (2)

proprietary pre-workout supplement

EXPERIMENTAL

Liquid IV pre-workout supplement powder

Dietary Supplement: proprietary pre-workout supplement

Control treatment

PLACEBO COMPARATOR

inactive/inert placebo mixture

Dietary Supplement: Control placebo

Interventions

Control placebo DIETARY_SUPPLEMENT

inactive/inert placebo mix

Control treatment

proprietary pre-workout supplement DIETARY_SUPPLEMENT

proprietary pre-workout supplement

proprietary pre-workout supplement

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males or females aged 18-55
• Must be recreationally trained or trained/developmental as previously defined (McKay et al., 2021)
• Able to read and write in English

You may not qualify if:

• Are not consistently taking, or will discontinue consuming other pre-workout supplements or dietary supplements, such as creatine, rhodiola, L-Theanine, glycerol, stimulants other than caffeine, or ingredients which may promote hydration or enhance physical performance within the past 2-weeks, and throughout the duration of the study.
• Willing to restrict caffeine for 24 hours prior to testing
• Will not participate in any strenuous exercise for a minimum of 72 hours prior to exercise performance assessments. Strenuous exercise as defined for this study includes ½ and full marathons (or more), heavy (i.e.,\>80% 1RM) lifting, and any high intensity, physical activity that could make your muscles sore.
• Sedentary: Individuals performing less than 150 minutes of moderate or 75 minutes of vigorous activity per week and engaging in resistance training fewer than 2 days per week, with no structured exercise routine.
• Highly trained/national level or professional athlete: Individuals training ≥5 days per week in structured programs, including NCAA Division II/III athletes, national/professional competitors, or those targeting top 20% sport-specific performance norms.
• Known diagnosis of any cardiovascular, metabolic, endocrine, or renal disease
• Recent musculoskeletal injury (\<3-months)
• Recent orthopaedic surgery (\<12-months)
• History or current malignancy
• Previous gastrointestinal surgery within the past 12 months
• Regular smoker
• Regular drinker (\>14 drinks per week)
• Current respiratory infection (i.e. cold) or high temperature (fever) within the past 4-weeks
• Presently using GLP-1 medications
• Individuals with cardiovascular, metabolic, or musculoskeletal disorders;

Sponsors & Collaborators

• Applied Science & Performance Institute: lead

Study Sites (1)

Applied Science & Performance Institute

Tampa, Florida, 33634, United States

Location

Study Officials

• Eric Sikorski, PhD

  Applied Science and Performance Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: randomized, double-blind, crossover study

Study Record Dates

• First Submitted: November 3, 2025
• First Posted: November 6, 2025
• Study Start: December 1, 2025
• Primary Completion: February 2, 2026
• Study Completion: February 9, 2026
• Last Updated: March 6, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)